Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Efficacy and Safety of a Novel Subcutaneous Formulation of CT- P13 over the 1- year Treatment Period and After Switching from Intravenous CT- P13 in Patients with Active Rheumatoid Arthritis: Results from Part 2 of Phase I/III Randomized Controlled Trial
- Authors
- 유대현
- Issue Date
- 10-Nov-2019
- Place
- Atlanta, USA
- Conference Name
- ACR 2019
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 2. Conference Papers
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.